Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins.
The present study was made to determine the value of drug skin tests in patients with cutaneous adverse drug reactions (CADRs) due to a synergistin (pristinamycin) and to determine the frequency of cross-reactions between synergistins. 29 patients were referred during the onset of the CADR due to pristinamycin: 18 with maculopapular rash, 9 erythrodermas, 1 angioedema and 1 Stevens-Johnson syndrome. They all had patch tests with pristinamycin and, in most cases, with other synergistins [virginiamycin and dalfopristin-quinupristin (DQ)], prick tests (10 cases) and intradermal tests (IDT) (5 cases). Skin tests with synergistins were positive in 27 cases, patch tests with pristinamycin in 20/29 cases (69%), prick tests with pristinamycin in 3/9 cases on immediate (1 case) or on delayed (2 cases) readings, and IDT with DQ in 4/5 cases. Cross-reactions between synergistins occurred in 9/22 with virginiamycin and in 7/8 cases with DQ. Skin tests with synergistins are useful in investigating CADR due to pristinamycin. Synergistins are composed of 2 chains (1 depsipeptide and 1 macrocyclic lactone) with many structural analogies between all synergistins. According to the chemical structures and our results, it seems advisable to avoid all synergistins in patients with CADR due to pristinamycin.
Barbaud
A
A
Dermatology Department, Fournier Hospital, 36 Quai de al Bataille, 54000 Nancy, France. a.barbaud@chu-nancy.fr
Trechot
P
P
Weber-Muller
F
F
Ulrich
G
G
Commun
N
N
Schmutz
J L
JL
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000494:pharmacology; D016022:Case-Control Studies; D003429:Cross Reactions; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D025762:Pristinamycin / Q000009:adverse effects* / Q000494:pharmacology; D012189:Retrospective Studies; D012882:Skin Tests; D013329:Structure-Activity Relationship; D014769:Virginiamycin / Q000009:adverse effects* / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D025762:Pristinamycin; D014769:Virginiamycin; C062940:quinupristin-dalfopristin